Radical journal gathers support

The scientific community appears to be fighting to convince Elsevier to continue to publish its only non-peer-reviewed journal, after the publisher began to linkurl:consider installing a traditional peer review system;http://www.the-scientist.com/blog/display/57121/ when the journal published a controversial paper supporting the arguments of AIDS deniers. Image: flicker/linkurl:meviola;http://www.flickr.com/photos/69659670@N00/ Despite the uproar that article created, the editor-in-chief of lin

Written byJef Akst

| 2 min read

Save for Later

Image: flicker/linkurl:meviola;http://www.flickr.com/photos/69659670@N00/

Despite the uproar that article created, the editor-in-chief of linkurl:Medical Hypotheses;http://www.elsevier.com/wps/find/journaldescription.cws_home/623059/description has received more than 150 letters of support for the journal's non-traditional publishing model, in which papers are chosen by the editor-in-chief, linkurl:Bruce Charlton.;http://www.buckingham.ac.uk/publicity/dofe/charlton.html "Medical Hypotheses has become an important vehicle for publishing exciting new ideas and information that is helping to shape the directions of medical research," linkurl:wrote;http://medicalhypotheses.blogspot.com/2010/02/medical-hypotheses-authors-letters-of.html linkurl:Paul W. Sherman;http://www.nbb.cornell.edu/sherman.shtml of Cornell University in New York. "Cancelling the journal, or massively altering its focus and editorial policies, would potentially deprive both the medical and biological communities of their only existing forum for interaction." Charlton, who has forwarded the majority of the letters on to Elsevier, is vying to keep the journal in its current form or have it discontinued altogether and not transformed into "an imposter having the same name," he wrote in an email to The Scientist. "I found it inspiring to realize that so many would take the trouble to write, and often at length," Charlton wrote. "These letters strongly reinforced my conviction that Medical Hypotheses, in its 35 years, has been a very worthwhile journal; one whose existence has made a significant and positive difference to the work of many scientists and scholars." The journal's editorial board also recently wrote to the publisher saying it did not approve of the proposals to introduce a peer-review system and exclude papers on controversial topics, linkurl:the Times Higher Education reported.;http://www.timeshighereducation.co.uk/story.asp?sectioncode=26&storycode=410489 Elsevier has not yet responded to the letter, Tom Reller, director of Corporate Relations at Elsevier, wrote in an email to The Scientist, and the fate of the journal is still undecided.
**__Related stories:__***linkurl:Radical journal's fate at risk;http://www.the-scientist.com/blog/display/57121/
[27th January 2010]*linkurl:Elsevier published 6 fake journals;http://www.the-scientist.com/blog/display/55679/
[7th May 2009]*linkurl:Journal plays with peer review;http://www.the-scientist.com/blog/display/55394/
[3rd February 2009]*linkurl:Tackling peer review bias;http://www.the-scientist.com/blog/display/54893/
[28th July 2008]

Meet the Author

Jef Akst

Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

View Full Profile

Radical journal gathers support

The Scientist ARCHIVES

Become a Member of

Meet the Author

Jef Akst

Related Research Resources

What Is the Amniotic Fluid Composed of?

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Advancing Drug Discovery with Complex Human In Vitro Models

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Maximizing Cancer Research Model Systems

Products

Product News

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform